請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/48495
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林榮耀 | |
dc.contributor.author | Ming-Te Peng | en |
dc.contributor.author | 彭銘得 | zh_TW |
dc.date.accessioned | 2021-06-15T06:59:12Z | - |
dc.date.available | 2016-03-03 | |
dc.date.copyright | 2011-03-03 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-01-26 | |
dc.identifier.citation | 1. Feo, F., Frau, M., Tomasi, M.L., Brozzetti, S. & Pascale, R.M. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med (Maywood) 234, 726-736 (2009).
2. Feitelson, M.A. et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene 21, 2593-2604 (2002). 3. Parkin, D.M., Stjernsward, J. & Muir, C.S. Estimates of the worldwide frequency of twelve major cancers. Bull World Health Organ 62, 163-182 (1984). 4. Suriawinata, A. & Xu, R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 24, 77-88 (2004). 5. Simonetti, R.G. et al. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 36, 962-972 (1991). 6. Leong, T.Y. & Leong, A.S. Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 7, 5-15 (2005). 7. El-Serag, H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36, S74-83 (2002). 8. Austin, H. et al. A case-control study of hepatocellular carcinoma and the hepatitis B virus, cigarette smoking, and alcohol consumption. Cancer Res 46, 962-966 (1986). 9. Hassan, M.M. et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36, 1206-1213 (2002). 10. Teoh, N.C. Proliferative drive and liver carcinogenesis: too much of a good thing? J Gastroenterol Hepatol 24, 1817-1825 (2009). 11. Frau, M., Biasi, F., Feo, F. & Pascale, R.M. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med 31, 179-193. 12. Yang, B.H. et al. [Changes of clinical aspect of primary liver cancer in China during the past 30 years--control study for 3,250 cases with primary liver cancer]. Zhonghua Yi Xue Za Zhi 83, 1053-1057 (2003). 13. Maddika, S. et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 10, 13-29 (2007). 14. Enserink, J.M. & Kolodner, R.D. An overview of Cdk1-controlled targets and processes. Cell Div 5, 11. 15. Hui, A.M., Makuuchi, M. & Li, X. Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology 45, 1635-1642 (1998). 16. Yamaguchi, H., Wyckoff, J. & Condeelis, J. Cell migration in tumors. Curr Opin Cell Biol 17, 559-564 (2005). 17. Wang, W. et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 64, 8585-8594 (2004). 18. Raftopoulou, M. & Hall, A. Cell migration: Rho GTPases lead the way. Dev Biol 265, 23-32 (2004). 19. Burridge, K. & Wennerberg, K. Rho and Rac take center stage. Cell 116, 167-179 (2004). 20. Sahai, E. & Marshall, C.J. RHO-GTPases and cancer. Nat Rev Cancer 2, 133-142 (2002). 21. Schmitz, A.A., Govek, E.E., Bottner, B. & Van Aelst, L. Rho GTPases: signaling, migration, and invasion. Exp Cell Res 261, 1-12 (2000). 22. Ridley, A.J. Rho proteins and cancer. Breast Cancer Res Treat 84, 13-19 (2004). 23. Joyce, J.A. & Pollard, J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 9, 239-252 (2009). 24. Danen, E.H. & Yamada, K.M. Fibronectin, integrins, and growth control. J Cell Physiol 189, 1-13 (2001). 25. Ritzenthaler, J.D., Han, S. & Roman, J. Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling. Mol Biosyst 4, 1160-1169 (2008). 26. Playford, M.P. & Schaller, M.D. The interplay between Src and integrins in normal and tumor biology. Oncogene 23, 7928-7946 (2004). 27. Grise, F., Bidaud, A. & Moreau, V. Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta 1795, 137-151 (2009). 28. Tcherkezian, J. & Lamarche-Vane, N. Current knowledge of the large RhoGAP family of proteins. Biol Cell 99, 67-86 (2007). 29. Kaibuchi, K., Kuroda, S. & Amano, M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 68, 459-486 (1999). 30. Takenawa, T. & Miki, H. WASP and WAVE family proteins: key molecules for rapid rearrangement of cortical actin filaments and cell movement. J Cell Sci 114, 1801-1809 (2001). 31. Bamburg, J.R. & Wiggan, O.P. ADF/cofilin and actin dynamics in disease. Trends Cell Biol 12, 598-605 (2002). 32. Parviz, F. et al. Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet 34, 292-296 (2003). 33. Hayhurst, G.P. et al. Morphogenetic competence of HNF4 alpha-deficient mouse hepatic cells. J Hepatol 49, 384-395 (2008). 34. Odom, D.T. et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 303, 1378-1381 (2004). 35. Sladek, F.M. Orphan receptor HNF-4 and liver-specific gene expression. Receptor 3, 223-232 (1993). 36. Ishiyama, T. et al. Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes. Cancer Sci 94, 757-763 (2003). 37. Hatzis, P., Kyrmizi, I. & Talianidis, I. Mitogen-activated protein kinase-mediated disruption of enhancer-promoter communication inhibits hepatocyte nuclear factor 4alpha expression. Mol Cell Biol 26, 7017-7029 (2006). 38. Cicchini, C. et al. Snail controls differentiation of hepatocytes by repressing HNF4alpha expression. J Cell Physiol 209, 230-238 (2006). 39. Chiba, H. et al. Activation of p21CIP1/WAF1 gene expression and inhibition of cell proliferation by overexpression of hepatocyte nuclear factor-4alpha. Exp Cell Res 302, 11-21 (2005). 40. Hwang-Verslues, W.W. & Sladek, F.M. Nuclear receptor hepatocyte nuclear factor 4alpha1 competes with oncoprotein c-Myc for control of the p21/WAF1 promoter. Mol Endocrinol 22, 78-90 (2008). 41. Lucas, B. et al. HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma. Oncogene 24, 6418-6431 (2005). 42. Yin, C. et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology 48, 1528-1539 (2008). 43. Cattin, A.L. et al. Hepatocyte nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier function of the adult intestinal epithelium. Mol Cell Biol 29, 6294-6308 (2009). 44. Battle, M.A. et al. Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci U S A 103, 8419-8424 (2006). 45. Yue, H.Y. et al. Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut 59, 236-246. 46. Zhong, W., Zhao, Y., McClain, C.J., Kang, Y.J. & Zhou, Z. Inactivation of hepatocyte nuclear factor-4{alpha} mediates alcohol-induced downregulation of intestinal tight junction proteins. Am J Physiol Gastrointest Liver Physiol 299, G643-651. 47. Tsai, C.C. et al. Large-scale sequencing analysis of the full-length cDNA library of human hepatocellular carcinoma. J Biomed Sci 10, 636-643 (2003). 48. Hall, A. Rho GTPases and the actin cytoskeleton. Science 279, 509-514 (1998). 49. Watanabe, T. et al. Interaction with IQGAP1 links APC to Rac1, Cdc42, and actin filaments during cell polarization and migration. Dev Cell 7, 871-883 (2004). 50. Noritake, J., Watanabe, T., Sato, K., Wang, S. & Kaibuchi, K. IQGAP1: a key regulator of adhesion and migration. J Cell Sci 118, 2085-2092 (2005). 51. Inoue, Y., Hayhurst, G.P., Inoue, J., Mori, M. & Gonzalez, F.J. Defective ureagenesis in mice carrying a liver-specific disruption of hepatocyte nuclear factor 4alpha (HNF4alpha ). HNF4alpha regulates ornithine transcarbamylase in vivo. J Biol Chem 277, 25257-25265 (2002). 52. Makita, T. et al. A developmental transition in definitive erythropoiesis: erythropoietin expression is sequentially regulated by retinoic acid receptors and HNF4. Genes Dev 15, 889-901 (2001). 53. Marcil, V. et al. Modification in oxidative stress, inflammation and lipoprotein assembly in response to hepatocyte nuclear factor 4 alpha knockdown in intestinal epithelial cells. J Biol Chem. 54. Hakoda, T. et al. A crucial role of hepatocyte nuclear factor-4 expression in the differentiation of human ductular hepatocytes. Lab Invest 83, 1395-1402 (2003). 55. Sladek, F.M., Zhong, W.M., Lai, E. & Darnell, J.E., Jr. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev 4, 2353-2365 (1990). 56. Taraviras, S., Monaghan, A.P., Schutz, G. & Kelsey, G. Characterization of the mouse HNF-4 gene and its expression during mouse embryogenesis. Mech Dev 48, 67-79 (1994). 57. Miquerol, L. et al. Expression of the L-type pyruvate kinase gene and the hepatocyte nuclear factor 4 transcription factor in exocrine and endocrine pancreas. J Biol Chem 269, 8944-8951 (1994). 58. Oshima, T. et al. Downregulated P1 promoter-driven hepatocyte nuclear factor-4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasis. Pathol Int 57, 82-90 (2007). 59. Sel, S., Ebert, T., Ryffel, G.U. & Drewes, T. Human renal cell carcinogenesis is accompanied by a coordinate loss of the tissue specific transcription factors HNF4 alpha and HNF1 alpha. Cancer Lett 101, 205-210 (1996). 60. Lenburg, M.E. et al. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 3, 31 (2003). 61. Mazure, N.M., Nguyen, T.L. & Danan, J.L. Severe hypoxia specifically downregulates hepatocyte nuclear factor-4 gene expression in HepG2 human hepatoma cells. Tumour Biol 22, 310-317 (2001). 62. Lazarevich, N.L. et al. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 39, 1038-1047 (2004). 63. Ning, B.F. et al. Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. Cancer Res 70, 7640-7651. 64. Sun, T. et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 51, 545-556. 65. van Zijl, F. et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 5, 1169-1179 (2009). 66. Matsuo, N. et al. Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 9, 240 (2009). 67. Giannelli, G., Bergamini, C., Fransvea, E., Sgarra, C. & Antonaci, S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 129, 1375-1383 (2005). 68. Hall, A. The cytoskeleton and cancer. Cancer Metastasis Rev 28, 5-14 (2009). 69. Hayashi, H. et al. Overexpression of IQGAP1 in advanced colorectal cancer correlates with poor prognosis-critical role in tumor invasion. Int J Cancer 126, 2563-2574. 70. White, C.D., Brown, M.D. & Sacks, D.B. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett 583, 1817-1824 (2009). 71. Mateer, S.C., Wang, N. & Bloom, G.S. IQGAPs: integrators of the cytoskeleton, cell adhesion machinery, and signaling networks. Cell Motil Cytoskeleton 55, 147-155 (2003). 72. Colletti, M. et al. Convergence of Wnt signaling on the HNF4alpha-driven transcription in controlling liver zonation. Gastroenterology 137, 660-672 (2009). 73. Schmitt-Graeff, A. et al. Coordinated expression of cyclin D1 and LEF-1/TCF transcription factor is restricted to a subset of hepatocellular carcinoma. Liver Int 25, 839-847 (2005). 74. Heuberger, J. & Birchmeier, W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol 2, a002915. 75. Whittaker, S., Marais, R. & Zhu, A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29, 4989-5005. 76. Rimassa, L. & Santoro, A. The present and the future landscape of treatment of advanced hepatocellular carcinoma. Dig Liver Dis 42 Suppl 3, S273-280. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/48495 | - |
dc.description.abstract | 肝癌是全世界最常發生的癌症之一,在台灣,肝癌自2004年列居癌症死亡病史第二位。雖然目前已有許多治療方式,但由於肝癌細胞易造成對鄰近組織與其他器官的高轉移性,使得肝癌患者的病情不甚樂觀。在普遍的癌細胞移動和侵襲過程中,通常地必須仰賴其細胞骨架的異常調控的機制作用以驅使細胞前進。
第四型肝細胞核因子(Hepatocyte nuclear factor 4α, HNF4α)是一種轉錄因子,調控許多參與細胞分化和正常肝細胞功能的基因表現,抑制細胞上皮-間質轉化(epithelial-mesenchymal transition, EMT)過程。近來研究亦認為HNF4α的表現量降低與肝癌細胞的演進過程有高度關聯性。為了深入探討HNF4α在癌細胞中調控的機制,我們利用基因重組的質體對低表現HNF4α的肝癌細胞株(SK-Hep1)增加HNF4α表現的影響,同時也使用核醣核酸(shRNA)專一性地對高表現HNF4α的肝癌細胞株(Huh6)抑制HNF4α的表現。研究發現HNF4α對細胞增生、週期、移動和侵襲的能力與細胞骨架之聚合方面皆表現了明顯抑制的作用。 在細胞生長方面,HNF4α可活化細胞週期蛋白依賴性激酶抑制因子(p21)的表現量,同時也抑制細胞週期素(Cyclin D1)和細胞週期蛋白依賴性激酶(Cdk1),使得細胞週期停止在G0/G1期,達到抑制細胞增生的效果。另一方面,HNF4α抑制間質蛋白(N-cadherin和Fibronectin)的表現量;由Fibronectin所活化的下游訊息傳遞分子FAK與Src,活性也因此降低。此外,HNF4α亦減低Cdc42的表現並造成Cofilin的活性上升,使得肌動蛋白纖維的聚合作用受到抑制;由雷射掃描共軛焦顯微鏡的觀察和肌動蛋白的分析結果顯示,表現HNF4α的細胞內,G-肌動蛋白單體比率提升,而纖維狀的F-肌動蛋白所佔比率則下降。 綜合上述,本研究結果顯示HNF4α表現的減少或喪失,將活化Fibronectin下游的訊息傳遞以促進細胞生長、移動與侵襲的能力和細胞骨架的聚合。因此,在肝癌細胞的增生/轉移過程中,HNF4α表現量的減少確實形成了重要的關鍵之一。 | zh_TW |
dc.description.abstract | Liver cancer is one of the leading cause of cancer and the second highest incidence of cancer death in Taiwan. Hepatocellular carcinoma (HCC) is a primary malignancy of the liver with poor prognosis, caused by metastatic cancers relapse. Hepatocyte nuclear factor 4α (HNF4α) is a transcription factor which has been shown to be down regulated in HCC. In this study, to address the role of HNF4α during the progression of HCC, an HNF4α expression plasmid was generated to study its effects on hepatoma cell lines (SK-Hep1with low expression of HNF4α), whereas shRNA was used on hepatoma cells Huh6 with high expression of HNF4α. The results showed that the gene expression level of HNF4α is correlated with epithelial phenotype and inversely associated with cell viability, cell cycle progression, organization of actin filament, migratory and invasive capacities of HCC cells. The suppressive effects of HNF4α on proliferation are achieved by up-regulating the expression of p21 and down-regulating the expression of cyclin D1 and cyclin dependent kinase 1 (Cdk1). Additionally, the expression of N-cadherin and fibronectin was down-regulated by HNF4α in HCC cells. We further examined the effects of HNF4α on focal adhesion kinase (FAK) and Src, and the results showed that knock-down of HNF4α expression had a significant activation effect on FAK and Src in HCC cells. Moreover, HNF4α also displayed significant suppressive effects on cell mobility by down regulation of Cdc42 expression and Rac1 activity to inhibit the formation of actin stress fiber. Down-regulation of cytoskeletons has been strongly implicated in HCC progression, particularly in cell migration and cell invasion. Taken together, the results indicate that HNF4α functions as an tumor suppressor gene and plays a role in proliferation, actin cytoskeletons, cell migration and invasion, in part via down regulating CCND1, Cdk1, fibronectin, p-FAK, p-Src, Rac1, N-cadherin and Cdc42. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T06:59:12Z (GMT). No. of bitstreams: 1 ntu-100-R97442014-1.pdf: 17038590 bytes, checksum: 0a5f35b3a130e13e7c3a8096b87688dc (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 致謝 I
Contents II List of figures VI Abbreviations used VIII 摘要 XI Abstract XIII Introduction 1 1. Hepatocellular carcinoma (HCC) 1 2. Proliferation 2 3. Metastasis 2 4. Hepatocyte nuclear factor 4α (HNF4α) 4 5. Strategy and Purpose 5 Materials and Methods 7 1. Materials 7 1.1 Antibodies 7 1.2 Enzymes 7 1.3 Reagents 8 2. Construction of a Hepatocyte Nuclear Factor 4α expression plasmid 8 2.1 Plasmid mini-preparation 8 2.2 PCR amplification 8 2.3 Purification of PCR products 9 2.4 Cloning PCR products into vectors 10 2.5 Screening of colonies by colony PCR and restriction enzyme digestion 10 3. Western blotting 11 3.1 Preparation of cell lysates 11 3.2 Quantification of protein concentration 11 3.3 Preparation of Sodium-dodecyl-sulfate-polyacrylamide gel electrophoresis 12 3.4 Preparation of protein samples and polyacrylamide gel electrophoresis 13 3.5 Semi-dry blotting 14 3.6 Immunoblotting 14 4. Cell culture 15 5. Transfection 15 6. MTT assay 16 7. Cell migration assay 17 8. Cell invasion assay 17 9. Wound healing assay 18 10. Chromatin Immunoprecipitation (ChIP) assay for HNF4α 18 11. Confocal microscopy analysis 21 12. Cell cycle analysis 21 13. G/F actin assay 22 14. GST-PBD pull down assay 23 14.1 Purification of GST-PBD 23 14.2 Rac1 activity assays 23 15. Co-Immunoprecipitation (ChIP) assay for IQGAP1 24 Results 25 1. Identification HNF4α as one of the key regulating genes in the molecular pathways in HCC 25 2. Overexpression of HNF4α inhibited the proliferation ability in HCC cells 26 3. Overexpression of HNF4α suppressed cell motility and the organization of the actin cytoskeleton of HCC cells 27 4. HNF4α down-regulated the gene expression of Cdc42, fibronectin and N-cadherin, and the activation of Rac1 and cofilin 29 5. HNF4α reduced the accumulation of IQGAP1 on leading edge via regulating Rac1 activity and Cdc42 expression 31 6. Association of HNF4α on the promoter regions of HNF4α-target gene 32 Discussion 33 Figures 39 Tables 59 References 61 | |
dc.language.iso | en | |
dc.title | 第四型肝細胞核因子抑制肝癌細胞的增生和轉移 | zh_TW |
dc.title | Hepatocyte nuclear factor 4α suppresses the proliferation and migration of hepatocellular carcinoma cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李德章,呂紹俊 | |
dc.subject.keyword | 第四型肝細胞核因子,肝癌,細胞增生,細胞移動與侵襲,細胞骨架,間質蛋白,細胞週期素與細胞週期蛋白依賴性激酶,抑制因子, | zh_TW |
dc.subject.keyword | HNF4α,HCC,migration,invasion,cytoskeletons,p21,CCND1,fibronectin,N-cadherin,Rac1,Cdc42, | en |
dc.relation.page | 66 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-01-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 16.64 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。